Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ADAPTIVE BIOTECHNOLOGIES CORPORATION

(ADPT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020

10/13/2020 | 04:05pm EDT

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter ended September 30, 2020 after market close on Tuesday, November 10, 2020. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics and drug discovery. We have two commercial products and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE MEDIA
Beth Keshishian
917-912-7195
media@adaptivebiotech.com

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

Primary Logo


© GlobeNewswire 2020
All news about ADAPTIVE BIOTECHNOLOGIES CORPORATION
06/14ADAPTIVE BIOTECHNOLOGIES CORP  : Submission of Matters to a Vote of Security Hol..
AQ
06/09New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine..
GL
06/03Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2..
GL
05/20Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Confer..
GL
05/07ADAPTIVE BIOTECHNOLOGIES  : Morgan Stanley Adjusts Adaptive Biotechnologies PT t..
MT
05/05ADAPTIVE BIOTECHNOLOGIES : Q1 Earnings Snapshot
AQ
05/05ADAPTIVE BIOTECHNOLOGIES  : First Quarter Earnings Presentation
PU
05/05ADAPTIVE BIOTECHNOLOGIES  : Management's Discussion and Analysis of Financial Co..
AQ
05/05ADAPTIVE BIOTECHNOLOGIES  : Earnings Flash (ADPT) ADAPTIVE BIOTECHNOLOGIES Posts..
MT
05/05ADAPTIVE BIOTECHNOLOGIES CORP  : Results of Operations and Financial Condition, ..
AQ
More news
Financials (USD)
Sales 2021 150 M - -
Net income 2021 -226 M - -
Net cash 2021 340 M - -
P/E ratio 2021 -24,4x
Yield 2021 -
Capitalization 5 535 M 5 535 M -
EV / Sales 2021 34,7x
EV / Sales 2022 25,0x
Nbr of Employees 622
Free-Float 98,4%
Chart ADAPTIVE BIOTECHNOLOGIES CORPORATION
Duration : Period :
Adaptive Biotechnologies Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ADAPTIVE BIOTECHNOLOGIES CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 60,00 $
Last Close Price 39,45 $
Spread / Highest target 82,5%
Spread / Average Target 52,1%
Spread / Lowest Target 19,1%
EPS Revisions
Managers and Directors
NameTitle
Chad Robins Chairman & Chief Executive Officer
Julie Rubinstein President
Chad M. Cohen Chief Financial & Accounting Officer
Harlan Robins Chief Scientific Officer
Lance Baldo Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ADAPTIVE BIOTECHNOLOGIES CORPORATION-33.28%5 535
EXACT SCIENCES CORPORATION-4.51%21 705
GUARDANT HEALTH, INC.-6.73%12 155
BGI GENOMICS CO., LTD.-7.47%7 557
INVITAE CORPORATION-21.57%6 553
CAREDX, INC22.35%4 614